Comparison of chemoembolization with CalliSpheres^® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.2129425651787
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. doi:10.1016/j.jhep.2018.03.019
   Google Scholar
• Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739. doi:10.1016/S0140-6736(02)07571-212049862
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171. doi:10.1053/jhep.2002.3315611981766
   PubMed Web of Science ®Google Scholar
• Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–773. doi:10.1002/hep.2389220564355
   PubMed Web of Science ®Google Scholar
• Lee JK, Chung YH, Song BC, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52–58. doi: 10.1046/j.1440-1746.2002.02664.x11895553
   PubMed Web of Science ®Google Scholar
• Kim YW, Kwon JH, Nam SW, et al. Sustained multiple organ ischaemia after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Exp Ther Med. 2018;15:1479–1483.29434732
   PubMed Web of Science ®Google Scholar
• Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2017;9:808–814. doi:10.4254/wjh.v9.i18.80828706579
   PubMedGoogle Scholar
• Zou JH, Zhang L, Ren ZG, et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016;17:510–517. doi:10.1111/1751-2980.1238027384075
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug Deliv. 2017;24:1011–1017. doi:10.1080/10717544.2016.126782228660787
   PubMed Web of Science ®Google Scholar
• Lee YK, Jung KS, Kim DY, et al. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: emphasis on the impact of tumor size. J Gastroenterol Hepatol. 2017;32:487–496. doi:10.1111/jgh.1350127503585
   PubMed Web of Science ®Google Scholar
• Cheung AH, Lam CS, Tam HS, et al. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2016;15:493–498. doi:10.1016/S1499-3872(16)60133-927733318
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52. doi:10.1007/s00270-009-9711-7.19908093
   PubMed Web of Science ®Google Scholar
• Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007;5:1100–1108. doi:10.1016/j.cgh.2007.04.02117627902
   PubMed Web of Science ®Google Scholar
• Guan YS, He Q, Jin Y, et al. Development of CalliSpheres(R) embolic microspheres. Zhonghua Gan Zang Bing Za Zhi. 2016;24:549–551.27784439
   PubMedGoogle Scholar
• Gorodetski B, Chapiro J, Schernthaner R, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27:526–535. doi:10.1007/s00330-016-4445-927277261
   PubMed Web of Science ®Google Scholar
• Rahman FA, Naidu J, Ngiu CS, et al. Conventional versus doxorubicin-eluting beads transarterial chemoembolization for unresectable hepatocellular carcinoma: a tertiary medical centre experience in Malaysia. Asian Pac J Cancer Prev. 2016;17:4037–4041. doi:10.7314/apjcp.2016.17.4.211927644658
   PubMedGoogle Scholar
• Chen P, Yuan P, Chen B, et al. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:75–85. doi:10.1016/j.clinre.2016.05.01327350573
   PubMed Web of Science ®Google Scholar
• Vesselle G, Quirier-Leleu C, Velasco S, et al. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26:1640–1648. doi:10.1007/s00330-015-3982-y26455721
   PubMed Web of Science ®Google Scholar
• Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2004;15:1209–1218. doi:10.1097/01.RVI.0000128123.04554.C115525739
   PubMed Web of Science ®Google Scholar
• Sellers MT, Huggins S, Kegley K, et al. Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:647–654. doi: 10.1016/j.jvir.2012.12.00323384831
   PubMed Web of Science ®Google Scholar
• Hansmann J, Evers MJ, Bui JT, et al. Albumin-bilirubin and platelet-albumin-bilirubin grades accurately predict overall survival in high-risk patients undergoing conventional transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2017;28:1224–1231 e1222. doi:10.1016/j.jvir.2017.05.02028688815
   PubMed Web of Science ®Google Scholar
• Wu X, Chen R, Zheng W, et al. Comprehensive analysis of factors affecting clinical response and short-term survival to drug-eluting bead transarterial chemoembolization for treatment in patients with liver cancer. Technol Cancer Res Treat. 2018;17:1533033818759878. doi:10.1177/153303381875987829739274
   PubMed Web of Science ®Google Scholar
• Gomes AS, Monteleone PA, Sayre JW, et al. Comparison of triple-drug transcatheter arterial chemoembolization (TACE) with single-drug TACE using doxorubicin-eluting beads: long-term survival in 313 patients. AJR Am J Roentgenol. 2017;209:722–732. doi:10.2214/AJR.17.1821928705059
   PubMed Web of Science ®Google Scholar
• Wang F, Yang JL, Yu KK, et al. Activation of the NF-kappaB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma. Mol Cancer. 2015;14:10. doi:10.1186/s12943-014-0278-925622857
   PubMed Web of Science ®Google Scholar
• Horikawa M, Miyayama S, Irie T, et al. Development of conventional transarterial chemoembolization for hepatocellular carcinomas in japan: historical, strategic, and technical review. Am J Roentgenol. 2015;205:764–773. doi:10.2214/AJR.15.1482526397324
   PubMed Web of Science ®Google Scholar